Comparison of the immunogenicity and safety of two 17D yellow fever vaccines

American Journal of Tropical Medicine and Hygiene

Volumn 60, Issue 6, 1999, Pages 1045-1050

  Lang, Jean ^a   Zuckerman, Jane ^b   Clarke, Paul ^c   Barrett, Peter ^c   Kirkpatrick, Christopher ^d   Blondeau, Christine ^a  

^a Pasteur Mérieux Connaught   (France)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c BRITISH AIRWAYS   (United Kingdom)

^d Chiltern International Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STAMARIL; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; LIVER FUNCTION; MULTICENTER STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VACCINATION; YELLOW FEVER;

EID: 0033049813     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.60.1045     Document Type: Article

References (22)

1. Monath TP, Tsai TF, 1997. Flaviviruses. Richman DD, Whitley RJ, Hayden FG, eds, Clinical Virology. New York: Churchill Livingstone. 1171-1175.
2. Nasidi A, Monath TP, DeCock K, Tomori O, Cordellier R, Olaleye OD, Harry TO. Adeniyi JA, Sorungbe OA, Ajose-Coker AO, 1989. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg 83: 401-406.
3. Robertson SE, Hull BP, Tomori O, 1996. Yellow fever: a decade of reemergence. JAMA 276: 1157-1162.
4. World Health Organization 1996. International Travel and Health: Vaccination Requirements and Health Advice. Geneva: World Health Organization.
5. Centers for Disease Control 1994. Health Information for International Travel. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Services.
6. 1990, Yellow fever vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 39(RR-6): 1-6.
7. Freestone DS, 1994. Yellow fever vaccine. Plotkin SA, Mortimer EA, eds. Vaccines. Second edition. Philadelphia: W. B. Saunders, 741-779.
8. Theiler M, 1951. The virus. Strode GK, ed. Yellow Fever, New York: McGraw Hill Book Co, Inc., 43-146.
9. Fox JP, Lennette EH, Monso C, Souza Aguias JB, 942. Encephalitis in man following vaccination with 17D yellow fever virus Am JHyg 36: 117-141.
10. World Health Organization, 1945. Standards for the manufacture and control of yellow fever vaccine. United Nations Relief and Rehabilitation Administration. World Health Organ Enidemiol Bull 1: 1-365.
11. Expert Committee on Biological Standardization, 1992. WHO Tech Rep Ser 822.
12. Guerra HL, Sardinha TM, da Rosa AP, Lima Costa MF, 1997. Effectiveness of the yellow fever vaccine 17D: an epidemiological evaluation in health services (in Spanish). Rev Panam Salud Publica 2: 115-120.
13. World Health Organization, 1998. Global Programme for Vaccines and Immunization: Vaccine Research and Development. 1998 Report of the Steering Committee on Epidemiology and Field Research. Geneva: WHO, GPV/VRD/SC/98.07.
14. Poirier MK, Poland GA, Jacobson RM, 1996. Parameters potentially affecting interpretation of immunogenicity and efficacy data in vaccine trials: are they adequately reported? Vaccine 14: 25-27.
15. De Madrid AT, Porterfield JS, 1969. A simple microculture method for the study of group B arboviruses Bull World Health Organ 40: 113-121.
16. World Health Organisation, 1976. Expert Committee on Biological Standardization: requirements for yellow fever vaccine. World Health Organ Tech Rep Ser 594: 23-29.
17. Expanded Programme on Immunization, 1996. Inclusion of yellow fever in the EPI, Gambia. Wkly Epidemiol Rec 71: 181-185.
18. The World Bank, 1993. World Development Report 1993: Investing in Health. Oxford, United Kingdom: Oxford University Press.
19. World Health Organization, 1983. International Health Regulations (1969) (amended in 1973 and 1981). Third annotated edition. Geneva: World Health Organization.
20. World Health Organization, 1996. Yellow fever vaccinating centres for international travel: amendments to 1991 publication. Wkly Epidemiol Rec 71: 69-70.
21. Oinusi, K. Akinkugbe FM, Akinwolere OAO, Fabiyi A, 1990. Safety and efficacy of yellow fever vaccine in children less than one year old. W Afr J Med 9: 200-213.
22. Dumas R, Forrat R, Lang J, Farinelli T, Loutan L, 1997. Safety and immunogenicity of administering a new inactivated hepatitis A vaccine (AVAXIM™) in association with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine Adv Ther 14: 160-167.